FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “GeoVax Labs, Inc Rises After Presenting Data From its Ongoing Covid-19 Vaccine Studies”
GeoVax Labs, Inc. (NASDAQ: GOVX) surged over 73% in premarket trading after the company presented data from ongoing studies of its preventive vaccine against COVID-19 on thursday.
Using its novel Modified Virus Ankara – Virus Like Particle platform, GeoVax has developed a design strategy for vaccines expected to induce broader immunity through inclusion of multiple structural and nonstructural proteins from the target pathogen.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.
For more information, please visit: GeoVax Labs, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.